Buy Cabozantinib 80 mg online, Buy Cometriq / Cabometyx online

Cabozanix (Cabozantinib) 80 mg (Cometriq/ Cabometyx) by Beacon Pharmaceuticals is used to treat Thyroid Cancer, Liver Cancer, Kidney Cancer(Renal Cell Carcinoma-RCC)

Cabozanix is the alternative & generic version of Cometriq/ Cabometyx by Exelixis. Cabozanix is manufactured by Beacon Pharmaceuticals Bangladesh which is the biggest pharmaceutical company in Bangladesh.

Therapeutic Class

Cytotoxic Chemotherapy

Pharmacology

In vitro biochemical and/or cellular assays have shown that Cabometyx inhibits the tyrosine kinase activity of MET, VEGFR-1, -2 and -3, AXL, RET, ROS1, TYRO3, MER, KIT, TRKB, FLT-3, and TIE-2.

These receptor tyrosine kinases are involved in both normal cellular function and pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, drug resistance, and maintenance of the tumor microenvironment.

Dosage

Recommended Dosage for Renal Cell Carcinoma: The recommended dosage of Cabozantinib is 60 mg once daily without food until the patient no longer experiences clinical benefit or experiences unacceptable toxicity.

Recommended Dosage for Hepatocellular Carcinoma: The recommended dosage of Cabozantinib is 60 mg once daily without food until disease progression or unacceptable toxicity.

Administration

Stop treatment with Cabometyx at least 28 days prior to scheduled surgery, including dental surgery. Do not substitute Cabozantinib tablets with cabozantinib capsules.

Do not administer Cabometyx with food. Administer at least 1 hour before or at least 2 hours after eating. Swallow Cabozantinib tablets whole. Do not crush Cabozantinib tablets.

Modify the dose for certain patients with hepatic impairment and for patients taking drugs known to strongly induce or inhibit CYP450

Interaction

Strong CYP3A4 inhibitors: Reduce the Cabometyx dosage if coadministration cannot be avoided. Strong CYP3A4 inducers: Increase the Cabozantinib dosage if coadministration cannot be avoided.

Side Effects

Cabozantinib may cause serious side effects, including:

bleeding (hemorrhage), a tear in your stomach or intestinal wall (perforation) or an abnormal connection between 2

parts of your body (fistula), blood clots, stroke, heart attack, and chest pain, high blood pressure (hypertension), diarrhea, a skin problem called hand-foot skin reaction, protein in your urine and possible kidney problems

Pregnancy & Lactation

Based on findings from animal studies and its mechanism of action, Cabometyx can cause fetal harm when administered to a pregnant woman. There is no information regarding the presence of Cabozantinib or its metabolites in human milk.

Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with Cabometyx and for 4 months after the final dose.

Precautions & Warnings

Hemorrhage: Do not administer Cabozantinib if recent history of hemorrhage.

Perforations and Fistulas: Monitor for symptoms. Discontinue Cabometyx for unmanageable fistula or GI perforation.

Thrombotic Events: Discontinue Cabometyx for myocardial infarction, cerebral infarction, or other serious thromboembolic events.

Hypertension and Hypertensive Crisis: Monitor blood pressure regularly. Interrupt for hypertension that is not adequately controlled with anti-hypertensive therapy. Discontinue Cometriq for hypertensive crisis or severe hypertension that cannot be controlled with

anti-hypertensive therapy. Diarrhea: May be severe. Interrupt Cometriq immediately until diarrhea resolves or decreases to Grade 1. Recommend standard antidiarrheal treatments.

Palmar-plantar erythrodysesthesia (PPE): Interrupt Cabozantinib treatment until PPE resolves or decreases to Grade 1. Proteinuria: Monitor urine protein. Discontinue for nephrotic syndrome.

Osteonecrosis of the jaw: Withhold Cabozantinib for at least 28 days prior to invasive dental procedures and for development of ONJ.

Wound complications: Withhold Cometriq for dehiscence or complications requiring medical intervention. Reversible posterior leukoencephalopathy syndrome (RPLS): Discontinue Cometriq.

Use in Special Populations

Pediatric Use: The safety and effectiveness of Cometriq in pediatric patients have not been established.

Geriatric Use: No overall differences in safety or effectiveness were observed between these patients and younger patients.

Renal Impairment: No dosage adjustment is recommended in patients with mild or moderate renal impairment.

Overdose Effects

One case of overdosage was reported following administration of another formulation of Cometriq; a patient inadvertently took twice the intended dose for 9 days.

The patient suffered Grade 3 memory impairment, Grade 3 mental status changes, Grade 3 cognitive disturbance, Grade 2 weight loss, and Grade 1 increase in BUN. The extent of recovery was not documented.

Storage Conditions

Store Cometriq at room temperature 20°C to 25°C